LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Almotriptan Orifarm
(Almotriptan)

SE/H/1644/01/DC

This module reflects the scientific discussion for the approval of Almotriptan Orifarm. The procedure was finalised on 2017-07-06. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se

I. INTRODUCTION

The application for Almotriptan Orifarm, 12.5 mg, film-coated tablet, is a generic application made according to Article 10(1) of Directive 2001/83/EC. The applicant, Orifarm Generics A/S applies through the Decentralised Procedure with Sweden acting as reference member state (RMS) and FI and NO as concerned member states (CMS).

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Almogran, 12,5 mg, film-coated tablet authorised in Sweden since 2001 with Almirall S.A. as marketing authorisation holder.The reference product used in the bioequivalence study is Almogran, 12,5 mg, film-coated tablet from UK with Almirall S.A. as marketing authorisation holder.

For approved indications, see the Summary of Product Characteristics.

For recommendations to the marketing authorisation not falling under Article 21a/22 of Directive 2001/83 and conditions to the marketing authorisation pursuant to Article 21a or 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

Bioequivalence was evaluated in one single-dose, two-way crossover study conducted in 32 healthy volunteers, comparing Almotriptan, 12.5 mg, film-coated tablets with Almogran, 12.5 mg, film-coated tablets under fasting conditions. The study was conducted at International Pharmaceutical Research Center in Amman, Jordan between 16/06/2012 and 02/07/2012. Blood samples were collected pre-dose and up to 24 hours post-dose. The study design is considered acceptable. Plasma concentrations of almotriptan were determined with adequately validated LC/MS/MS method. For AUC_{0-t} and C_{max} the 90% confidence interval for the ratio of the test and reference products fell within the conventional acceptance range of 80.00-125.00%.

Based on the submitted bioequivalence study Almotriptan Orifarm is considered bioequivalent with Almogran.

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

IV.3 Risk Management Plan

A Risk Management Plan (RMP) for the Almotriptan Orifarm 12.5 mg tablets (version 1.0), with data lock point and date of final sign off 2016-06-30; was submitted within this application. The RMP has been updated (version 1.2) with date of final sign off on 16 December 2016.

Safety specification
The following summary of safety concerns have been proposed by the Applicant.

Summary of safety concerns	
Important identified risks	• Myocardial ischemia/infarction • Cerebrovascular events • Peripheral vascular events • Medication errors including medication overuse headache (MOH) •
Important potential risks	• Use during pregnancy • Use during lactation
Missing information	-

Pharmacovigilance Plan
Routine pharmacovigilance is suggested and no additional pharmacovigilance activities are proposed by the Applicant, which is endorsed.

Risk minimisation measures
Routine risk minimisation is suggested and no additional risk minimisation activities are proposed by the Applicant, which is endorsed.

Summary of the RMP
The RMP is approved.

V. USER CONSULTATION

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to Almotriptan Sandoz leaflet, DK/H/2162/001/DC (for content) and Alfonac leaflet, SE/H/1142/01/DC (for layout). The bridging report submitted by the applicant has been found acceptable.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The quality of the generic product, Almotriptan Orifarm, is found adequate. There are no objections to approval of Almotriptan Orifarm, from a non-clinical and clinical point of view. The product information is acceptable.

The application is therefore recommended for approval.

List of recommendations not falling under Article 21a/22 of Directive 2001/83 in case of a positive benefit risk assessment

N/A

List of conditions pursuant to Article 21a or 22 of Directive 2001/83/EC

N/A

VII. APPROVAL

The Decentralised procedure for Almotriptan Orifarm, 12.5 mg, film-coated tablet was positively finalised on 2017-07-06.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se